No needles at all
A syringe to measure with, not to inject. Nothing to learn, nothing to dispose of.
The single most common reason people ask for this version.
Back to all peptides
Coming soon
Tirzepatide (Sublingual)
Once-Weekly Dual GIP/GLP-1, No Needle
Metabolic
A once-weekly sublingual tirzepatide liquid for weight management — no needle, provider-titrated.
- No needles and no injection technique to learn
- Two incretin pathways engaged rather than one
- A single once-weekly dose
- A dose your provider raises gradually to limit side effects
- Ongoing provider review before every refill
Dosage4 mL bottle, 1 mL per weekly dose; strength set by your provider
AdministrationSublingual liquid, once weekly
Compounded in the U.S.A.
Tirzepatide (Sublingual) is coming soon. It isn't available to order yet — check back shortly.
About
What is Tirzepatide (Sublingual)?
This is the same molecule as the injectable tirzepatide — a dual GIP and GLP-1 receptor agonist — prepared as an oral liquid. You draw 1 mL with the syringe provided, hold it under your tongue for 45 seconds, then swallow. Once a week, same day each week.
It exists for people who will not use a needle. That is a legitimate reason, and a medication nobody takes does not work — but if injecting is acceptable to you, the injectable version has the evidence behind it and your provider will likely recommend it.
The honest caveat: sublingual and oral delivery of incretin agonists is much less studied than subcutaneous injection. These are large molecules and they cross mucous membranes poorly compared with something injected into fat. Part of the dose absorbs under the tongue and the rest is swallowed.
Dosing works as it does for the injectable — your provider sets the strength and raises it gradually, reviewing you before each refill. This is a compounded preparation, not an FDA-approved product.
Why people explore Tirzepatide (Sublingual)
A clearer path forward.
Two receptors, one weekly dose
The same dual GIP/GLP-1 agonism as the injectable, in an oral liquid.
A 4 mL bottle holds four weekly 1 mL doses.
Honest about the trade-off
Less evidence behind this route than injection. We would rather say so than sell around it.
If needles are not a barrier for you, your provider will probably recommend the injectable.
What it helps with
Designed for these concerns.
- No needles and no injection technique to learn
- Two incretin pathways engaged rather than one
- A single once-weekly dose
- A dose your provider raises gradually to limit side effects
- Ongoing provider review before every refill
Ideal for
Adults pursuing medically supervised weight management who will not use injections · People with a needle phobia · Anyone who wants a provider reviewing their dose before each refill
The science
How Tirzepatide (Sublingual) works.
Tirzepatide activates both the GLP-1 receptor, which reduces appetite and slows gastric emptying, and the GIP receptor, the other major incretin pathway. Held under the tongue, some of the dose is absorbed through the oral mucosa and the remainder is swallowed. Sublingual delivery is less studied than injection, and your provider will discuss whether it fits your goals.
01
Signal
Tirzepatide (Sublingual) is delivered by sublingual liquid, once weekly, entering circulation and reaching the tissues where it acts.
02
Cellular response
Tirzepatide activates both the GLP-1 receptor, which reduces appetite and slows gastric emptying, and the GIP receptor, the other major incretin pathway. Held under the tongue, some of the dose is absorbed through the oral mucosa and the remainder is swallowed. Sublingual delivery is less studied than injection, and your provider will discuss whether it fits your goals.
03
Outcome
Over the following weeks, most people report gradual change in the areas Tirzepatide (Sublingual) targets: weight management without injections.
Sublingual liquid, once weeklyCompounded in the U.S.A. at a 503A pharmacyProvider-prescribed
What the research shows
Backed by published science.
- Tirzepatide is the first dual GIP/GLP-1 receptor agonist brought to clinical use
- The oral mucosa is a well-characterised absorption route for a range of medications
- Evidence for sublingual delivery of incretin agonists is considerably thinner than for injection
- Dose escalation over several months is standard, and exists specifically to limit gastrointestinal side effects
Lab tested medications
for quality & potency
Our medication is delivered from a state-licensed pharmacy in our network, right to your door when you need it.
Third-party quality control testing
Compounded in U.S. pharmacies
Lab tested for quality & potency
Our pharmacies perform third-party testing through FDA and DEA registered labs to run quality control checks for every compounded lot. They test four key characteristics associated with quality and safety.
Potency Test
PassedPerformed on every batch to confirm the active ingredient is present at the labeled concentration. Your vial contains exactly what it should.
Sterility Test
PassedTests for the presence of bacteria, fungi, and other microorganisms. Every batch is tested and must meet the requirements of USP 797.1.
Endotoxin Test
PassedScreens for bacterial endotoxins that can cause fever or adverse reactions. Every batch is tested and must not exceed the threshold limits defined in USP 85.
pH Test
PassedAssesses the acid/base balance to ensure minimal irritation upon injection and confirm the solution is within the correct range for subcutaneous administration.
FAQ
Common questions about Tirzepatide (Sublingual).
Patient reviews
What patients are saying.
No reviews yet. Be the first verified patient to share your experience.
This is not medical advice. Every patient's experience differs and not everyone qualifies for peptide therapy. All reviews are from verified PeRx patients and are published as submitted. Peptide therapy requires a valid prescription from a licensed provider.
Your safety, first
Important safety information.
- Not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2
- Not for use during pregnancy, while breastfeeding, or if planning pregnancy within 6 months
- Discuss any history of pancreatitis, gallbladder disease, or gastroparesis with your provider
- Tell your provider if you take insulin or a sulfonylurea — the dose may need adjusting
- Nausea, vomiting, diarrhoea, and constipation are common, especially after a dose increase
- Seek care for severe abdominal pain, particularly pain that spreads to your back
- Requires licensed provider supervision
All prescriptions are issued by a licensed US provider after reviewing your intake.
Side effects, contraindications, and what to discuss with your provider before starting.
Read safety information
Last updated April 2026
Medical disclaimer
The information provided on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Peptide therapy requires a valid prescription from a licensed healthcare provider. Individual results may vary. No specific outcomes are guaranteed.
The peptides on this site are not FDA-approved. They are compounded by licensed pharmacies under provider supervision. Certain peptides are prohibited by WADA and major sports organizations. Statements on this page have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Ready to start with Tirzepatide (Sublingual)?
Take our 2-minute assessment. A licensed US provider reviews and, if appropriate, prescribes a protocol shipped to your door.